Takeda Pharmaceutical (TAK) Share-based Compensation (2018 - 2026)

Takeda Pharmaceutical's Share-based Compensation history runs 9 years deep, the most recent figure standing at $125.7 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 8.79% year-over-year to $125.7 million in Q1 2026; TTM through Mar 2026 was $482.7 million, a 0.73% increase from a year earlier, with the FY2026 full-year figure at $483.5 million, up 1.07% from the prior year.
• Share-based Compensation grew to $125.7 million in Q1 2026 per TAK's latest filing, from $115.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $144.5 million in Q3 2024 and bottomed at $95.0 million in Q2 2022.
• The 5-year median for Share-based Compensation is $116.7 million (2022), against an average of $117.5 million.
• Across the five-year window, Share-based Compensation climbed 21.73% in 2022 and declined 12.28% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $116.7 million in 2022, then climbed by 8.43% to $126.6 million in 2023, then slipped by 4.88% to $120.4 million in 2024, then slipped by 3.9% to $115.7 million in 2025, then grew by 8.66% to $125.7 million in 2026.
• Per Business Quant, the three latest TAK Share-based Compensation figures stand at $125.7 million (Q1 2026), $115.7 million (Q4 2025), and $127.1 million (Q3 2025).